business
Dexcom’s Bet Beyond Diabetes
Dexcom CEO Jake Leach joined Bloomberg Open Interest to explain why continuous glucose monitors are becoming much bigger than diabetes devices. He says GLP-1 drugs are actually boosting CGM adoption and defends the company’s growth outlook. He also lays out Dexcom’s push into mainstream metabolic he
Read full story on Bloomberg Markets → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop